Physician profile
Jocelyn E Hewitt
NPI 1407047129
$9,043.70
in general payments reported to CMS, 2019-2025
40 companies · $576 in 2025
The $576 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $562 · 2021: $2,825 · 2022: $1,946 · 2023: $1,733 · 2024: $1,193 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,502.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,036.54 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,285.96 | 2020-2024 | Mounjaro, Jardiance |
| Abbott Laboratories | $620.31 | 2020-2025 | Freestyle Libre 3 |
| Amgen INC. | $511.80 | 2019-2025 | Evenity, Tepezza, Prolia |
| Medtronic, INC. | $484.21 | 2021-2025 | Minimed 780g |
| Bayer Healthcare Pharmaceuticals INC. | $447.15 | 2021-2024 | |
| Dexcom, INC. | $348.89 | 2021-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $345.34 | 2020-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $308.55 | 2020-2023 | Jardiance |
| Corcept Therapeutics | $305.50 | 2020-2023 | Korlym |
| Sanofi-Aventis U.S. LLC | $265.03 | 2020-2024 | |
| Beta Bionics, INC. | $261.06 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Xeris Pharmaceuticals, INC. | $255.89 | 2020-2024 | Recorlev, Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $237.90 | 2023-2025 | |
| Insulet Corporation | $221.07 | 2019-2023 | Omnipod |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jocelyn Hewitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.